Palbociclib, a selective inhibitor of CDK4 and CDK6 developed by Pfizer (USA), was demonstrated to be effective in a phase III study involving 521 patients who had hormone-receptor-positive metastatic breast cancer, and FDA approved its application for breast cancer in February 201539,40. Here, CDK4 is linked to breast carcinoma.